MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Price, Quote, News and Overview
NASDAQ:MLTX - Nasdaq - KY61559X1045 - Common Stock - Currency: USD
MLTX Quote, Performance and Key Statistics
37.6
-1.66 (-4.24%)
The current stock price of MLTX is 37.6 USD. In the past month the price increased by 12.9%. In the past year, price decreased by -4.04%.
MLTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.31 | 332.73B | ||
| AMGN | AMGEN INC | 13.29 | 148.31B | ||
| GILD | GILEAD SCIENCES INC | 12.78 | 123.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 60.56B | ||
| ARGX | ARGENX SE - ADR | 327.86 | 38.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 25.03B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.31B | ||
| NTRA | NATERA INC | N/A | 21.77B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.04B | ||
| BIIB | BIOGEN INC | 7.41 | 17.17B |
Related stock screener links
About MLTX
Company Profile
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 100 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Company Info
MOONLAKE IMMUNOTHERAPEUTICS
Dorfstrasse 29
Zug ZUG CH
Employees: 100
Phone: 41415108022
MOONLAKE IMMUNOTHERAPEUTICS / MLTX FAQ
What is the stock price of MOONLAKE IMMUNOTHERAPEUTICS today?
The current stock price of MLTX is 37.6 USD. The price decreased by -4.24% in the last trading session.
What is the ticker symbol for MOONLAKE IMMUNOTHERAPEUTICS stock?
The exchange symbol of MOONLAKE IMMUNOTHERAPEUTICS is MLTX and it is listed on the Nasdaq exchange.
On which exchange is MLTX stock listed?
MLTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MOONLAKE IMMUNOTHERAPEUTICS stock?
22 analysts have analysed MLTX and the average price target is 77.44 USD. This implies a price increase of 105.94% is expected in the next year compared to the current price of 37.6. Check the MOONLAKE IMMUNOTHERAPEUTICS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MOONLAKE IMMUNOTHERAPEUTICS worth?
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) has a market capitalization of 2.41B USD. This makes MLTX a Mid Cap stock.
How many employees does MOONLAKE IMMUNOTHERAPEUTICS have?
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) currently has 100 employees.
What are the support and resistance levels for MOONLAKE IMMUNOTHERAPEUTICS (MLTX) stock?
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) has a support level at 39.26 and a resistance level at 42.33. Check the full technical report for a detailed analysis of MLTX support and resistance levels.
Should I buy MOONLAKE IMMUNOTHERAPEUTICS (MLTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MLTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MLTX, evaluating the profitability, health, valuation and growth aspects
- MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Sales and EPS estimates to see what analysts future expectations are.
- MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Chart to make your own analysis
- MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Latest news and press-releases to stay up to date.
Does MOONLAKE IMMUNOTHERAPEUTICS (MLTX) stock pay dividends?
MLTX does not pay a dividend.
When does MOONLAKE IMMUNOTHERAPEUTICS (MLTX) report earnings?
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) will report earnings on 2025-05-08, before the market open.
What is the Price/Earnings (PE) ratio of MOONLAKE IMMUNOTHERAPEUTICS (MLTX)?
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.89).
What is the Short Interest ratio of MOONLAKE IMMUNOTHERAPEUTICS (MLTX) stock?
The outstanding short interest for MOONLAKE IMMUNOTHERAPEUTICS (MLTX) is 12.38% of its float. Check the ownership tab for more information on the MLTX short interest.
MLTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MLTX. When comparing the yearly performance of all stocks, MLTX is a bad performer in the overall market: 64.67% of all stocks are doing better.
MLTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MLTX. While MLTX has a great health rating, there are worries on its profitability.
MLTX Financial Highlights
Over the last trailing twelve months MLTX reported a non-GAAP Earnings per Share(EPS) of -1.89. The EPS decreased by -148.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.89% | ||
| ROE | -26.62% | ||
| Debt/Equity | 0 |
MLTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to MLTX. The Buy consensus is the average rating of analysts ratings from 22 analysts.